Overview

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.
Phase:
Phase 1
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd